Prognostic impact of MPV for non–squamous non–small cell lung cancer patients who received front line chemotherapy in combination with bevacizumab: A retrospective analysis.

Not Applicable

• Conditions: non& #8211; small cell lung cancer; squamous non&amp

• Registration Number: JPRN-UMIN000011018
• Lead Sponsor: Kansai Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-24
• Study Completion: 2013-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who lack adequate medical record. Patients who received thoracic irradiation with curative intention. Patients who were diagnosed as LC-NEC.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biological effects of bevacizumab to MPV.

Secondary Outcome Measures

Name	Time	Method
Contribution of MPV for survival of NSCLC patients who received chemotherapy in combination with Bevacizumab.